Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Johnson & Johnson Reports 77% Tumor Response Rate in Head and Neck Cancer Trial

Johnson & Johnson Reports 77% Tumor Response Rate in Head and Neck Cancer Trial

MT newswireMT newswire2026/10/26 08:35
04:35 AM EDT, 10/26/2026 (MT Newswires) -- Johnson & Johnson (JNJ) said late Sunday that its investigational Rybrevant Faspro combination achieved a 77% confirmed response rate in a phase 1b/2 study of patients with recurrent or metastatic head and neck cancer, excluding HPV-associated oropharyngeal cancer. The regimen achieved complete responses in 14% of the 22 patients, with 65% of responses ongoing at a median follow-up of 10.6 months. The median time to response was 9.4 weeks, and the one-year survival rate was 77%, the company said. The findings support further evaluation in the ongoing phase 3 OrigAMI-5 study. The most common side effects included anemia, low albumin levels, reduced platelet counts and mouth inflammation. Johnson & Johnson said an application for Rybrevant Faspro in later-line head and neck cancer is under Priority Review with the US Food and Drug Administration.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

South Korean think tanks significantly raise 2027 economic growth forecasts, betting on continued AI chip boom

The Korea Development Institute (KDI) raised its economic growth forecast for this year and next on Wednesday, betting that the global artificial intelligence (AI) boom will continue to drive semiconductor exports and investment, helping the South Korean economy maintain its growth momentum.

智通财经•2026/11/18 04:12

SQM.US Q3 profit misses expectations; lithium price declines but demand outlook remains “encouraging”

SQM.US still reports seeing "encouraging" potential demand trends.

智通财经•2026/11/18 03:16

Mizuho: Consecutive system outages in the US trigger stockpiling surge! With short-term demand boosted, Costco (COST.US) sales momentum is expected to remain strong.

According to a report by Mizuho Securities analysts, following a series of recent system failures in the United States, consumers have started stockpiling essential goods, leading to a short-term surge in demand for Costco, a members-only retailer.

智通财经•2026/11/18 03:07
Mizuho: Consecutive system outages in the US trigger stockpiling surge! With short-term demand boosted, Costco (COST.US) sales momentum is expected to remain strong.